Slayton R E, Blessing J A, Rettenmaier M, Ball H
Department of Medicine, Rush-Presbyterian St. Luke's Medical Center, Chicago, IL.
Invest New Drugs. 1989 Nov;7(4):337-40. doi: 10.1007/BF00173764.
Twenty-six patients with recurrent adenocarcinoma and adenosquamous carcinoma of the uterine cervix were treated with diaziquone (AZQ) 22.5 mg/m2 diluted in 150 ml normal saline every three weeks. In the absence of adverse effects the second dose and all subsequent doses were escalated to 30 mg/m2. All patients had measurable disease and only 11 had received prior chemotherapy. Two partial responses were noted among 15 patients with no prior chemotherapy, while no responses were observed among 11 previously treated patients. The major toxicity was leukopenia and thrombocytopenia. Median progression-free interval was 1.5 months and median survival was 4 months. AZQ displays minimal activity against recurrent nonsquamous carcinoma of the cervix at the dose and schedule used.
26例复发性子宫颈腺癌和腺鳞癌患者接受了重氮醌（AZQ）治疗，剂量为22.5mg/m²，用150ml生理盐水稀释，每三周给药一次。若无不良反应，第二剂及后续所有剂量增至30mg/m²。所有患者均有可测量的病灶，仅11例曾接受过化疗。15例未接受过化疗的患者中有2例出现部分缓解，而11例曾接受过治疗的患者未观察到缓解。主要毒性为白细胞减少和血小板减少。无进展生存期的中位数为1.5个月，总生存期的中位数为4个月。在所使用的剂量和给药方案下，AZQ对复发性子宫颈非鳞状细胞癌的活性极小。
